During the corresponding time, Vaxart Inc saw a revenue deteriorated by -31.58 % year on year, sequentially revenue fell by -30.7 %. While revenue at the Vaxart Inc 's corporate clients
Vaxart Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including healthcare benefit programs, private third-party payors, Medicaid, and other state programs. Its market segments include federal healthcare programs such as Medicare, Medicaid, and the Children’s Health Insurance Program, as well as private third-party payors and state healthcare programs. Physicians and teaching hospitals are recipients of payments or transfers of value from manufacturers of drugs, devices, biological products, and medical supplies.
Vaxart Inc. has recently announced the publication of an important study showcasing the immunogenicity and safety of its first-generation oral pill Norovirus vaccine candidate, particularly focusing on elderly adults. This development comes at a crucial time, given the heightened vulnerability of this demographic to gastrointestinal infections, including norovirus, which can lead to severe health complications.The study s results demonstrate that the oral Norovirus vaccine candidate not only elicits a robust immune response but also presents a favorable safety profile in elderly participants. These findings could pave the way for a promising addition to vaccination strategies aimed at protecting older adults...
: This article presents an overview of recent developments in Vaxart s COVID-19 vaccine research, following the favorable review from an Independent Data Safety Monitoring Board (DSMB) regarding the initial safety assessments of its Phase 2b clinical trial. The ongoing search for effective COVID-19 vaccines is critical in the global fight against the pandemic. Vaxart, a biotechnology company focusing on oral vaccines, has made significant progress in this area with its innovative candidate. The most recent announcement revealed that the DSMB recommended the continuation of Vaxart s Phase 2b clinical trial based on preliminary safety data. Study Overview: The Phase 2b clinical trial is designed to assess the ...
Vaxart Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including healthcare benefit programs, private third-party payors, Medicaid, and other state programs. Its market segments include federal healthcare programs such as Medicare, Medicaid, and the Children’s Health Insurance Program, as well as private third-party payors and state healthcare programs. Physicians and teaching hospitals are recipients of payments or transfers of value from manufacturers of drugs, devices, biological products, and medical supplies.
Sources:
Vaxart Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Vaxart Inc’s corporate clients.
For your research, we’ve provided 9 tables on Vaxart Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
0.19 %